These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35067505)

  • 1. Prevalent Drug Usage Practices in Adults and Children With Idiopathic Inflammatory Myopathies: Registry-Based Analysis From the MyoCite Cohort.
    Mehta P; Rathore U; Naveen R; Chatterjee R; Agarwal V; Aggarwal R; Gupta L
    J Clin Rheumatol; 2022 Mar; 28(2):89-96. PubMed ID: 35067505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: A systematic literature review.
    Nosadini M; Mohammad SS; Toldo I; Sartori S; Dale RC
    Eur J Paediatr Neurol; 2019 Jan; 23(1):7-18. PubMed ID: 30318435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J; Yu H; Wang H; Zhang X; Feng K
    J Neuroimmunol; 2022 Feb; 363():577790. PubMed ID: 34959021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.
    Huapaya JA; Silhan L; Pinal-Fernandez I; Casal-Dominguez M; Johnson C; Albayda J; Paik JJ; Sanyal A; Mammen AL; Christopher-Stine L; Danoff SK
    Chest; 2019 Nov; 156(5):896-906. PubMed ID: 31238042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
    Huang W; Wang L; Xia J; Li W; Wang M; Yu J; Li Q; Wang B; Pan J; Du L; Ma J; Tan H; Chang X; Lu C; Zhao C; Lu J; Zhou L; ZhangBao J; Quan C;
    Eur J Neurol; 2022 Aug; 29(8):2343-2354. PubMed ID: 35398950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y; Wang CJ; Wang BJ; Zeng ZL; Guo SG
    J Neurol Sci; 2018 Feb; 385():192-197. PubMed ID: 29406904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu's arteritis.
    Kaymaz-Tahra S; Bayindir O; Ince B; Ozdemir İsik O; Kutu ME; Karakas O; Yildirim TD; Ademoglu Z; Ediboglu ED; Uludogan BCE; Ilgin C; Bilge NSY; Kasifoglu T; Akar S; Emmungil H; Onen F; Omma A; Kanitez NA; Yazici A; Cefle A; Inanc M; Aksu K; Keser G; Direskeneli H; Alibaz-Oner F
    Semin Arthritis Rheum; 2024 Jun; 66():152446. PubMed ID: 38669786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
    Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
    J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of rituximab, mycophenolate, methotrexate, and cyclophosphamide versus azathioprine as maintenance therapy in antineutrophil cytoplasmic antibody-associated vasculitis: A Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Int J Clin Pharmacol Ther; 2022 Feb; 60(2):97-105. PubMed ID: 34622770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort.
    Naveen R; Rathore U; Agarwal V; Gupta L
    Rheumatol Int; 2021 Mar; 41(3):551-563. PubMed ID: 33423071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.
    Campochiaro C; Farina N; De Luca G; Batani V; Trignani G; Vignale D; Palmisano A; Matucci-Cerinic M; Dagna L
    Arthritis Res Ther; 2024 Apr; 26(1):79. PubMed ID: 38570792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: results after 12 months of treatment. German Pediatric Renal Transplantation Study Group.
    Staskewitz A; Kirste G; Tönshoff B; Weber LT; Böswald M; Burghard R; Helmchen U; Brandis M; Zimmerhackl LB
    Transplantation; 2001 Mar; 71(5):638-44. PubMed ID: 11292293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
    Contreras G; Tozman E; Nahar N; Metz D
    Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease.
    Chang X; Zhang J; Li S; Wu P; Wang R; Zhang C; Wu Y
    Mult Scler Relat Disord; 2023 Apr; 72():104571. PubMed ID: 36905816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L; Tian J; Dong X; Jia Z; Sun Y; Guo L; Tan G; Li B
    Neurol Sci; 2022 Apr; 43(4):2651-2658. PubMed ID: 34585292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
    Poupart J; Giovannelli J; Deschamps R; Audoin B; Ciron J; Maillart E; Papeix C; Collongues N; Bourre B; Cohen M; Wiertlewski S; Outteryck O; Laplaud D; Vukusic S; Marignier R; Zephir H;
    Neurology; 2020 Apr; 94(15):e1645-e1656. PubMed ID: 32170036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate].
    Hafraoui S; Dewit O; Marteau P; Cosnes J; Colombel JF; Modigliani R; Cortot A; Lémann M
    Gastroenterol Clin Biol; 2002 Jan; 26(1):17-22. PubMed ID: 11938035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07).
    Horinouchi T; Sako M; Nakanishi K; Ishikura K; Ito S; Nakamura H; Oba MS; Nozu K; Iijima K
    BMC Nephrol; 2018 Nov; 19(1):302. PubMed ID: 30382824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation.
    Zuckermann A; Klepetko W; Birsan T; Taghavi S; Artemiou O; Wisser W; Dekan G; Wolner E
    J Heart Lung Transplant; 1999 May; 18(5):432-40. PubMed ID: 10363687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.